The immunosuppressive activity of various anticancer drugs has been evaluated by its effect on skin homograft survival in 45 patients. Patients with no evident advanced malignant disease and cancer patients receiving no therapy showed a mean skin homograft survival time of 8 days. Among the various types of anticancer therapy utilized, the drugs AB 132, hydroxyurea, mitomycin C and methotrexate with folinic acid each gave a significant prolongation of skin homograft survival. Neither the degree of drug toxicity nor difference in blood type or sex significantly altered the skin homograft survival under this study.
No takes yet. Share an insight, caveat, or question.
Görgün et al. (1966) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: